Camrelizumab Plus Anlotinib in Patients With Recurrent Sporadic Mismatch Repair Deficient Endometrial Cancer (CAN-RESPOND): a Single-arm, Multicentre, Phase 2 Study
Latest Information Update: 30 Sep 2022
At a glance
- Drugs Camrelizumab (Primary) ; Catequentinib (Primary)
- Indications Endometrial cancer
- Focus Therapeutic Use
- Acronyms CAN-RESPOND
Most Recent Events
- 26 Sep 2022 New trial record